Skip to content

Effect of intravenous Carnitine on anemia in hemodialysis patients

Evaluation of the effect of intravenous Carnitine on hemoglobin and hematocrit level in chronic renal disease patients who are under hemodialysis treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201010044865N1
Enrollment
29
Registered
2010-11-18
Start date
2004-06-17
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Hemodialysis. Condition 2: Anaemia. Chronic renal failure Anaemia in chronic diseases classified elsewhere

Interventions

Intervention 1: Intervention: carnitine, 1 gr interavenous, 3 times a week (after each dialysis session) for 3 months (36 sessions). Intervention 2: Control: dirtillor water, 1 gr intravenous, (3 time
Treatment - Drugs
Placebo
Intervention: carnitine, 1 gr interavenous, 3 times a week (after each dialysis session) for 3 months (36 sessions)
Control: dirtillor water, 1 gr intravenous, (3 times a week (after each dialysis session), for 3 months (36 sessions)

Sponsors

Zanjan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Hb less than10mg/dl, patients who had dialysed at least for one year, ferritin more than or equal to 100, SI/TIBC more than 20%, normal LFT, PTH less than or equal to 150pg/ml, negative ß-HCG in female patients Exclusion criteria: receiving carnitine in 2 months prior to the study, pregnancy (positive ß-HCG), Liver disease, ferritin less than 100, SI/TIBC less than 20%, PTH more than 150pg/ml

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Hb. Timepoint: Before and after the intervention. Method of measurement: cell counter.;Hct. Timepoint: Before and after the intervention. Method of measurement: cellcounter.

Secondary

MeasureTime frame
Ferritine. Timepoint: before intervention. Method of measurement: Selectra Autoanalyzer.;TIBC. Timepoint: befor intervention. Method of measurement: Autonalizer selectra.;Liver Function Test. Timepoint: before intervention. Method of measurement: Selectra Autoanalyzer.;Paratormon Hormone. Timepoint: before intervention. Method of measurement: Selectra Autoanalyzer.;Pregnancy test-BHCG. Timepoint: before intervention. Method of measurement: Statfax Eliza.;Serum iron. Timepoint: before intervention. Method of measurement: Selectra Autoanalyzer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Khodaverdi

Zanjan University of Medical Sciences

maryamkhodaverdi@yahoo.com+98 24 2526 5000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026